Compare ACCO & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACCO | OCGN |
|---|---|---|
| Founded | 1893 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.3M | 419.8M |
| IPO Year | 2005 | 2014 |
| Metric | ACCO | OCGN |
|---|---|---|
| Price | $4.22 | $1.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $5.00 | ★ $9.75 |
| AVG Volume (30 Days) | 608.8K | ★ 4.8M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 9.26% | N/A |
| EPS Growth | ★ 141.51 | 31.58 |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $1,524,700,000.00 | N/A |
| Revenue This Year | $3.10 | N/A |
| Revenue Next Year | $0.89 | $1,718.38 |
| P/E Ratio | $21.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.81 | $0.93 |
| 52 Week High | $4.39 | $2.73 |
| Indicator | ACCO | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 57.81 | 41.34 |
| Support Level | $3.73 | $1.13 |
| Resistance Level | $4.36 | $1.58 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 73.00 | 25.81 |
ACCO Brands Corp is a consumer, technology and business branded products company providing brands and product solutions used in schools, homes and at work. Its brands include At-A-Glance, Barrilito, Buro, Esselte, Five Star, Foroni, GBC, Hilroy, Kensington, Leitz, Mead, PowerA, Quartet, Rapid, Swingline and Tilibra. The Company's product categories include gaming and computer accessories, storage and organization, notebooks, shredding, laminating and binding machines, dry erase boards and do-it-yourself tools. The Company operates through two segments, Americas and International. Americas includes the U.S., Canada, Brazil, Mexico and Chile, and International includes EMEA, Australia, New Zealand and Asia. Its products are sold in the U.S., Europe, Australia, Canada, Brazil and Mexico.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").